These agents lead to improved outcomes in patients with CLL, even among those with high-risk features, such as del17p13 or TP53 mutation and unmutated immunoglobulin heavy chain (IGHV) genes. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.